Drug Profile
Cobolimab - AnaptysBio/GSK
Alternative Names: Anti-TIM-3-antibody-GSK; GSK-4069889; TSR 022; WBP 296ALatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator AnaptysBio
- Developer AnaptysBio; GSK; TESARO; University of Pittsburgh
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Cervical cancer; Liver cancer; Malignant melanoma
- Phase I Solid tumours
Most Recent Events
- 11 Mar 2024 Phase-II clinical trials in Cervical cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT06238635)
- 26 Jul 2023 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Poland, Italy, Sweden, Spain, Russia, Romania, Romania, Netherlands, Mexico, Germany, Canada, Brazil, Argentina, France, South Korea, Australia, USA, United Kingdom (IV)
- 05 Jul 2022 Cobolimab is still in phase I trials for Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (NCT02817633)